One of the world's most devastating diseases is malaria, responsible for at least a million deaths annually, despite global efforts to combat it. Researchers from the Perelman School of Medicine at the University of Pennsylvania, working with collaborators from Drexel University, The Children's Hospital of Philadelphia, and Johns Hopkins University, have identified a protein in human blood platelets that points to a powerful new weapon against the disease. Their work was published in this months' issue of Cell Host and Microbe.
Malaria is caused by parasitic microorganisms of the Plasmodium genus, which infect red blood cells. Recent research at other universities showed that blood platelets can bind to infected red blood cells and kill the parasite, but the exact mechanism was unclear. The investigators on the Cell Host and Microbe paper hypothesized that it might involve host defense peptides (HDP) secreted by the platelets.
"We eventually found that a single protein secreted when platelets are activated called human platelet factor 4 [hPF4] actually kills parasites that are inside red cells without harming the red cell itself," explains senior author Doron Greenbaum, PhD, assistant professor of Pharmacology, whose team studies innovative ways to fight malaria. The hPF4 targets a specific organelle of the Plasmodium falciparum parasite called the digestive vacuole, which essentially serves as its "stomach" for the digestion of hemoglobin. The investigators found that hPF4 destroys the vacuole with a deadly speed of minutes or even seconds, killing the parasite without affecting the host cell.
While host defense peptides appear to be attractive therapeutic agents, the expense of manufacturing this protein lessens its potential impact on the treatment of malaria. Greenbaum and colleagues set out to discover whether synthetic molecules mimicking the structure of HDPs could have similar beneficial effects against the Plasmodium parasite. After screening approximately 2000 small molecule HDP mimics (smHDPs) developed by biotech company PolyMedix, Inc. of Radnor, PA, Greenbaum and his team found that "all of the best hits had the same mechanism of action against Plasmodium parasites."
Like the natural hPF4 found in platelets, the most effective smHDPs tested targeted only infected red blood cells, attacking and destroying the parasite in exactly the same way, but with even greater potency and speed. "The smHDPs get into infected red cells and lyse or basically destroy the digestive vacuole or stomach of the parasite more rapidly than the hPF4 protein," Greenbaum notes. "The protein from platelets is about 25 times less potent, but the surprising thing is they act with the same mechanism. With ease, within seconds, they destroy the vacuole of the parasite."
Greenbaum's team settled on two compounds, PMX1207 and PMX207, for testing in mouse models of malaria. Both compounds significantly decreased parasitic growth and greatly improved survival rates, providing further confirmation of the potential of smHDPs as antimalarial agents. The work, Greenbaum says, shows that "we can translate a natural arm of the innate immune system in platelets to drug-like small molecules that we are honing to become potent, selective, potentially less toxic, and cheaper to make as an antimalarial."
Aside from their great effectiveness, smHDPs may have several other advantages over other antimalarial therapies. As Plasmodium inevitably adapts and becomes resistant to a particular drug therapy, the efficacy of that treatment decreases and survival rates drop. By mimicking the body's own natural defenses, the new HDP-centered approach could avoid that pitfall. "Certainly with malaria we've had a lot of problems in the last 20 years with resistance," Greenbaum explains. "One of the unique features of the synthetic HDPs is that studies show that pathogens have a difficult time generating resistance to them, because they attack membranes, not proteins. So they might be intrinsically more difficult to become resistant against."
Although Greenbaum's team focused mostly on the chronic red-blood-cell stage of malaria, their HDP-mimic also shows promise against other stages of the disease. "We think that the mimics would be useful as a transmission-blocking therapeutic," Greenbaum says. "In other words, you prevent transmission from human to mosquito and therefore back to human again. We have positive data for those two stages. It's becoming increasingly more important in antimalarial drug development that people think more and more about multistage inhibition."
The next step for Greenbaum's team is to further hone the selectivity and potency of the smHDP compounds, while developing them into drugs that can be orally administered. As Greenbaum explains, practical antimalarials need to be "taken as pills rather than having to be used intravenously, which is not going to be appropriate for treatment in endemic countries, especially in more rural environments."
University of Pennsylvania School of Medicine: http://www.uphs.upenn.edu/news/
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
UN assistant secretary general says deadly outbreak, which has been blamed on UN troops, demands decisive action
Caffeine is the drug many of us can't live without – but do you have any idea how much is in your daily hit?
Warmer temperatures are causing malaria to spread in the African and South American highlands, traditionally havens from the disease, scientists say.
How best to achieve success is a highly contentious issue, but politicians should remember that a good start in life is key
A second child seems to have been cleared of the AIDS virus, thanks to heavy-duty drugs started just hours after birth. This spring researchers plan to test that approach in 60 more newborns.
A report finds that azodicarbonamide wasn't just in Subway's bread: It's in hundreds of foods. While it has been linked to asthma in factory workers, the additive poses no known risk to consumers.
Army initiative to research suicides in the US military released its first three studiesAmanda Holpuch
The luxury fibre can be fashioned into screws and plates that could hold broken bones together while they heal, before biodegrading when no longer needed
Middle-aged people on a high-protein diet are at greater risk of dying from cancer, claims a study, but critics say firm evidence is lacking
In an exclusive interview with National Geographic, Nora Volkow, director of the National Institute on Drug Abuse, shares her concerns about the consequences of legalizing the drug.